Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies.

Results for Galcanezumab‐Treated Patients Without Initial Treatment Response at Month 1 or Month 2 (NR‐2) Similar to the patterns observed with the NR‐1 groups, response with continued treatment followed a decreasing trend based on the category of early improvement, though in general, the percentages of patients were lower for each response outcome.

also in 47,180 other papers